

April 30, 2014  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

**Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights  
(Stock Option) to the Company's Directors**

Symbio Pharmaceuticals Limited (“the Company”) announces that the following details have finalized today regarding the stock acquisition rights to be issued to the Company's Directors as stock options (the 32nd Series Symbio Stock Option) based on the resolution of the Board of Directors' meeting on April 15, 2014.

1. Number of stock acquisition rights

2,520

2. Class and number of stocks to be issued upon exercise of the stock acquisition rights

The Company's common stock: 252,000 shares

3. Amount to be paid for stock options and calculation method

(1) Amount to be paid per one stock option : 22,900 yen

(2) Amount to be paid per one share : 229 yen

The person who receives the allotment of stock acquisition rights shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.

(Note)

For further details of the stock acquisition rights, please refer to the Company's press release dated April 15, 2014, “Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors.”

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125